Eli Lilly and Company (LLY)vsSomalogic Inc (SLGC)
LLY
Eli Lilly and Company
$1,131.42
-1.21%
HEALTHCARE · Cap: $1.01T
SLGC
Somalogic Inc
$9.91
0.00%
HEALTHCARE · Cap: $396.23M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 88306% more annual revenue ($72.25B vs $81.72M). LLY leads profitability with a 35.0% profit margin vs -159.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SLGC
Avoid29
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.7% — below average capital efficiency
Revenue declined 47.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SLGC
SLGC has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : SLGC
The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while SLGC is a turnaround play — different risk/reward profiles.
SLGC carries more volatility with a beta of 1.64 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 29/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Somalogic Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
SomaLogic Inc. (SLGC) is a leading biotechnology firm revolutionizing the field of precision medicine through its proprietary SomaScan® platform, which specializes in protein biomarker discovery and analysis. Leveraging an extensive library of proteins, the company is dedicated to developing advanced diagnostics and therapeutic applications targeting critical health issues such as cancer, cardiovascular diseases, and metabolic disorders. Positioned at the forefront of the biomarker industry, SomaLogic not only drives innovation in both research and clinical environments but also forges strategic partnerships to broaden its impact and accelerate the adoption of its transformative technologies. With a commitment to data-driven health solutions, SomaLogic is focused on enhancing patient outcomes and tailoring therapeutic strategies to individual needs, making it a key player in the future of personalized medicine.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?